Avita Medical is a clinical and commercial company developing and marketing a range of respiratory and regenerative products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in EMEA countries and Australia.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products. Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the American OTC stock market under the ticker symbol AVMXY.
ReCell, spray-on skin
ReCell is a stand-alone, rapid, autologous cell harvesting, processing and delivery technology that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells, accelerating the healing process, eliminating tissue rejection, minimizing scar formation and reintroducing normal pigmentation, vascularization and innervation in the treated wound area. The procedure is performed on site at bedside and takes approximately 25 min to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars. February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment. In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority to raise money toward commercializing the product on the U.S. market. September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries. September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval, and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program. September 20, 2018 Avita Medical's ReCell wound care device received FDA PMA approval.
In addition to the US studies for ReCell in burns and scars, ReCell is being studied in a number of small scale post-marketing studies in Europe for venous leg ulcers, Vitiligo, acne scars, scar remodeling, facial rejuvenation, treatment of donor graft sites, and hard to heal burn wounds in the elderly.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
